Sanne de Haas

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

Eric Van Cutsem, Sanne de Haas, Yoon‐Koo Kang et al. · Journal of Clinical Oncology · 2012 · 484 citations

Medicine, Oncology, Pharmacology +17

Subjective Sleep Disturbance in Patients with Partial Epilepsy: A Questionnaire‐based Study on Prevalence and Impact on Quality of Life

Al de Weerd, Sanne de Haas, Andreas Otte et al. · Epilepsia · 2004 · 268 citations

Medicine, Neurology, Epilepsy +15

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

Solange Peters, Rolf A. Stahel, Lukas Bubendorf et al. · Clinical Cancer Research · 2018 · 230 citations · Full text

Medicine, Oncology, Pharmacology +17

Functional validation of a genetic locus in the VEGFR-1 tyrosine kinase (TK) domain as a predictive marker for bevacizumab

Bart Claes, Paul Delmar, Betül T. Yesilyurt et al. · Research Portal (Queen's University Belfast) · 2012 · 194 citations · Full text

Medicine, Cancer Biology, Oncology +17

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

Diether Lambrechts, Bart Claes, Paul Delmar et al. · The Lancet Oncology · 2012 · 187 citations

Medicine, Genetics, Oncology +10